From GlobeNewswire: 2024-11-22 09:00:00

The Genome Editing Market was valued at USD 7.99 billion in 2023, projected to reach USD 32.72 billion by 2032, with a CAGR of 16.98%. CRISPR technology drives growth in healthcare, agriculture, and biotech. Challenges include ethical concerns and regulations. Leading companies include Merck KGaA, Editas Medicine, and CRISPR Therapeutics.

Genetic engineering dominated the market in 2023 at 50% share, crucial for agriculture, biotech, and healthcare. Clinical applications are the fastest-growing segment with a projected CAGR of 25%, focusing on precision medicine and gene therapies. CRISPR/Cas9 technology led in 2023 with 55% market share, while TALENs/MegaTALs are the fastest-growing technologies with a projected CAGR of 22%.

Ex-vivo delivery methods held a 65% market share in 2023, involving editing cells outside the body before reintroduction. Key regions covered include North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. The market offers significant growth potential driven by technological advancements in genome editing across various sectors. Ex-vivo editing is highly successful for blood-related genetic disorders like sickle cell anemia, offering better control over the editing process. Genome editing market key segments include applications in genetic engineering, clinical applications, technology, delivery methods, and end-users. North America leads in market share due to research investments and leading genome editing companies. Recent developments include Precision BioSciences focusing on in vivo gene editing therapies and South Africa allowing heritable human genome editing. SNS Insider offers market analysis reports to help clients navigate changing circumstances with accurate data and insights.



Read more at GlobeNewswire: Genome Editing Market Size Projected to Reach USD 32.72